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ARTICLE
Epidemiology
Performance of DNA methylation assays for detection of high-
grade cervical intraepithelial neoplasia (CIN2+): a systematic
review and meta-analysis
Helen Kelly 1,2, Yolanda Benavente3, Miquel Angel Pavon1, Silvia De Sanjose3,4, Philippe Mayaud2 and Attila Tibor Lorincz5
BACKGROUND: To conduct a meta-analysis of performance of DNA methylation in women with high-grade cervical intraepithelial
neoplasia (CIN2+).
METHODS: Medline and Embase databases were searched for studies of methylation markers versus histological endpoints. Pooled
sensitivity, speciﬁcity and positive predictive value (PPV) for CIN2+ were derived from bivariate models. Relative sensitivity and
speciﬁcity for CIN2+ compared to cytology and HPV16/18 genotyping were pooled using random-effects models.
RESULTS: Sixteen thousand three hundred thirty-six women in 43 studies provided data on human genes (CADM1, MAL, MIR-124-2,
FAM19A4, POU4F3, EPB41L3, PAX1, SOX1) and HPV16 (L1/L2). Most (81%) studies evaluated methylation assays following a high-risk
(HR)-HPV-positive or abnormal cytology result. Pooled CIN2+ and CIN3+ prevalence was 36.7% and 21.5%. For a set speciﬁcity of
70%, methylation sensitivity for CIN2+ and CIN3+ were 68.6% (95% CI: 62.9–73.8) and 71.1% (95% CI: 65.7–76.0) and PPV were
53.4% (95% CI: 44.4–62.1) and 35.0% (95% CI: 28.9–41.6). Among HR-HPV+ women, the relative sensitivity of methylation for CIN2+
was 0.81 (95% CI: 0.63–1.04) and 1.22 (95% CI: 1.05–1.42) compared to cytology of atypical squamous cells of undetermined
signiﬁcance, or greater (ASCUS+) and HPV16/18 genotyping, respectively, while relative speciﬁcity was 1.25 (95% CI: 0.99–1.59) and
1.03 (95% CI: 0.94–1.13), respectively.
CONCLUSION: DNA methylation is signiﬁcantly higher in CIN2+ and CIN3+ compared to ≤CIN1. As triage test, DNA methylation
has higher speciﬁcity than cytology ASCUS+ and higher sensitivity than HPV16/18 genotyping.
British Journal of Cancer https://doi.org/10.1038/s41416-019-0593-4
BACKGROUND
Invasive cervical cancer (ICC) is one of the most common female
cancers in low and middle-income countries (LMIC), where 85%
of the estimated 570,000 global annual cases occur and is the
leading cause of cancer deaths among women in these
settings.1 ICC is one of the most preventable and treatable
forms of cancer, as long as it is detected early and managed
effectively. In May 2018, the Director-General of the World
Health Organization (WHO) made a global call for action towards
the elimination of ICC calling for more innovative technologies
for detection of precancerous lesions and better strategies to
increase ICC screening coverage and uptake.2 There is strong
evidence that high-risk human papillomavirus (HR-HPV) DNA
based screening is more sensitive for the detection of high-
grade CIN (CIN2+) and is effective in prevention of ICC
compared to cervical cytology and visual inspection.3 However,
HPV testing detects many transient infections, meaning that its
speciﬁcity for high-grade CIN is low,4 which has important
implications for screening women with high prevalence of HR-
HPV. Novel methods are required that are sensitive enough to
detect clinically relevant HPV needing colposcopy referral but
with high speciﬁcity to rule out HPV-positive women without
evidence of disease, thereby avoiding repeat testing which can
result in substantial loss to follow-up,5 as well as avoiding
unnecessary referrals for colposcopy, which increase the work-
load and costs to the services. DNA methylation of human genes
and HPV virus occur during HR-HPV infection and precancerous
tissue progression, leading to alterations in the functions of
gene products regulating tumour suppression.6,7 Such aberrant
DNA methylation may help distinguish non-progressive HPV
infections from those that will progress to cancer. Increased
DNA methylation has been shown to be associated with
increasing persistence of HR-HPV genotypes,8 severity of CIN
lesions9 and risk of invasive cancer.10
Recent studies evaluating DNA methylation of human genes
and the HPV virus for detection of HPV related lesions included
different human genes and HPV genotypes. Furthermore, these
studies varied in the CpG (cytosine followed by guanine)
dinucleotide sites chosen, many of which occur in the human
genome, in contrast to the HPV genome, which does not have any
clearly discernible CpG islands.6 Previous systematic reviews have
summarised the association and performance of DNA methylation
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for CIN2+ and CIN3+ detection,6,8,9,11 although none have yet
quantiﬁed the performance in a meta-analysis.
The aim of this review and meta-analysis is to evaluate the
performance of various DNA methylation markers (human genes
and HPV virus) for detection of CIN2+ and CIN3+. The novelty of
our review is that it evaluates: (i) the association of host and HPV
methylation positivity with increasing grades of CIN (Analysis 1); (ii)
the pooled sensitivity, speciﬁcity and positive predictive value
(PPV) of DNA methylation markers for the detection of CIN2+ and
CIN3+ in a triage setting (i.e. following HR-HPV-positive test or
abnormal cytology; Analysis 2) and (iii) the relative sensitivity and
relative speciﬁcity of DNA methylation markers compared to
HPV16/18 genotyping and cytology (using a cut-off of
atypical squamous cells of undetermined signiﬁcance, or greater
[ASCUS+] or low-grade squamous intraepithelial lesions, or
greater [LSIL+]), for the detection of CIN2+ and CIN3+ in a triage
setting (Analysis 3).
METHODS
Study outcomes
Studies were included if they reported the percentage of DNA
methylation according to CIN grade, or sensitivity and speciﬁcity
of the DNA methylation assays for the detection of the outcome,
or if the receiver operating characteristic (ROC) curve was
provided from which sensitivity and speciﬁcity estimates could
be obtained.
Studies were included if methylation markers were assessed
against a histological endpoint of CIN grade 2 or higher (CIN2/3,
CIN2+ or CIN3+ which can include carcinoma in situ and ICC).
Studies with cytological endpoint assessment only were excluded
because of the lower sensitivity for cytology measures in detection
of high-grade disease.12
Search
Medline, Embase and Cochrane databases were searched using
the following search terms: DNA methylation [Title/Abstract] OR
epigenetic [Title/Abstract] OR methylation [MeSH Terms] AND
nucleic acids [MeSH Terms] OR CpG islands [MeSH Terms] AND
HPV [Title/Abstract] OR human papillomavirus [Title/Abstract] OR
carcinogenesis [MeSH Terms] OR Cervical Intraepithelial Neopla-
sia/ or intraepithelial neoplasia [Title/Abstract]. The search
included all papers published up to 10 December 2018. All
abstracts were screened by one author (HK). Full-text copies of
relevant publications were obtained and assessed for eligibility by
two authors (H.K. and A.L.). Consensus was reached on potential
relevance.
Inclusion and exclusion criteria
Studies reporting methylation within biopsy specimens were
excluded as we aimed to evaluate the performance of DNA
methylation assays as a potential primary screening or triage tests
when cervical swabs would be used. Studies that reported only
crude percentage methylation estimates without a validated cut-
off for CIN2+ detection were excluded as they were not veriﬁed or
validated. Studies were excluded if cancers represented greater
than 10% of all samples and it was not possible to separately
analyse the cancers, the CIN2 and the CIN3, due to the risk of
spectrum bias related to the fact that the majority of cancers have
very high levels of methylation.
Studies not in the English language or conference abstracts
were excluded due to difﬁculty in assessing the quality of the
methodology, as were studies with fewer than 25 participants,
which could result in an unacceptably imprecise effect
measurement. Whereby publications provided DNA methylation
measures using a combination set of gene markers, the DNA
methylation of the individual markers as well as the combination
panel were presented separately in the results. The combination
tests were positive when any of the included gene markers were
positive.
Our review was restricted to DNA methylation markers where
there were 4 or more studies evaluating the performance of
an individual marker (to reduce the potential heterogeneity when
pooling a small number of studies), or if the marker had been
evaluated as part of a large population-based screening study.
Studies reporting only DNA methylation of HPV16 were included
given the small number of studies evaluating DNA methylation of
other HPV types.
Data extraction
From the consensus list, data were extracted by one author (HK)
using a standardised form. For all studies, the following variables
were recorded: year of study, study location, origin (country) of
study population, outcomes of interest (histological conﬁrmed
lesion CIN2+/CIN3+/ICC), DNA methylation marker evaluated,
DNA methylation positive among CIN2+/CIN3+ (true positives),
and ≤CIN1 (false-positives), and DNA methylation negative among
≤CIN1 (true-negatives) and CIN2+/CIN3+ (false-negatives),
where given.
Statistical analysis
Analysis 1. The percentage methylation (methylation positivity)
was extracted for each grade of CIN (≤CIN1, CIN2, CIN3 and ICC)
according to pre-deﬁned thresholds established or if pre-deﬁned
thresholds were not available, methylation positivity was calcu-
lated from ROC curves based on a set speciﬁcity of 70% for
CIN2+/CIN3+ detection by one author (HK) and validated by a
second author (AL). Crude (unadjusted) Odds Ratios (OR) and 95%
Conﬁdence Intervals (CI) were calculated for methylation positivity
associated with each grade of discrete grades of high-grade CIN
(CIN2, CIN3 and ICC) compared to CIN1 or normal (≤CIN1).
Random-effects meta-analysis were used to estimate pooled
effects to account for between-study heterogeneity and hetero-
geneity was examined using the I2 statistic.13 Sub-group analyses
by DNA methylation marker were performed to compare pooled
effects and heterogeneity.
Analysis 2. The numbers of true positives, false positives, true
negatives and false negatives were extracted where available,
obtained using study-speciﬁc thresholds to deﬁne methylation
positivity. Where several thresholds for methylation positivity were
reported or where only ROC curves were presented, sensitivity
data were extracted based on a threshold that produced a pre-
deﬁned set speciﬁcity of 70% and separately a set speciﬁcity
of 50%.
The bivariate model14 was used to estimate pooled sensitivity
and speciﬁcity using metandi and midas in STATA, whereby pairs
of sensitivity and speciﬁcity are jointly analysed, incorporating any
correlation that might exist between these two measures using a
random-effects approach. Individual meta-analyses were per-
formed for each of the human gene and HPV methylation
markers. Because methylation markers are not independent of
each other and given that most methylation markers perform
better combined in a panel, a meta-analysis of combination
markers was also performed, where available. To account for
correlation between sensitivity and speciﬁcity, we used the
hierarchical summary receiver operating characteristic (HSROC),15
which allows for threshold effects and between- and within-study
variability, by allowing both test accuracy to vary across studies.
Heterogeneity in the Forest Plots was assessed by visually
examining the conﬁdence intervals of individual studies.
A bivariate logitnormal random-effects model16 was used to
estimate pooled PPV from the observed prevalence of CIN2+ and
CIN3+ (Model 1). To account for varying observed CIN2+/CIN3+
prevalence in included studies, the pooled sensitivity and
speciﬁcity estimates obtained using the bivariate model14 were
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used to generate a pooled PPV for varying expected CIN2+ and
CIN3+ prevalence using PPV= Prev*SE/[Prev*SE+(1 − Prev)*(1 −
Spec)]17 (Model 2). We assumed no change in performance
of DNA methylation assays with increasing prevalence of
CIN2+/CIN3+.
Analysis 3. Relative sensitivity and relative speciﬁcity and 95%
Conﬁdence Interval (CI) of DNA methylation assays for CIN2+
and CIN3+ detection were compared to other test strategies
most widely reported, including HPV16/18 genotyping and
cervical cytology (ASCUS+ and LSIL+) evaluated as triage tests
following a HR-HPV-positive test. Where studies did not restrict
inclusion to HR-HPV-positive women only, the performance of
DNA methylation assays was compared to that of qualitative HR-
HPV DNA-based tests (Hybrid Capture II or PCR). Only those
studies that provided direct head-to-head comparison of
the two methods on the same population were included. The
data on true positive, false positive, true negative and
false negative for each test method and for each study were
extracted into Excel spreadsheet and imported into SAS. The
sensitivity and speciﬁcity of DNA methylation were compared to
that cytology and/or HPV16/18 genotyping using metadas in
SAS,18 which allows comparison of test method through
inclusion of test method as a covariate.19 We used sensitivity
estimates for DNA methylation assays based on a threshold to
achieve 70% speciﬁcity where studies allowed.
For each of the three analyses, separate sub-analyses were
conducted for discrete outcomes of CIN2+ and CIN3+. Data
were analysed using Stata (version 16) and SAS (version 9.4).
Methodological quality assessment
Study quality was assessed using the QUADAS-2 tool for the
quality assessment of diagnostic accuracy studies.20 Assessments
were based on: participant selection characteristics (location,
inclusion and exclusion criteria, study size and age distribution);
proportion of women with CIN2+/CIN3+ included; whether the
index test (DNA methylation assay) and reference test (histology)
were well described; indication for biopsy (i.e. whether all women
had biopsy taken irrespective of screening or triage test
abnormality) and whether there was independent validation of
histopathology diagnosis (Supplementary Tables 1, 2).
Studies were ranked in quality/robustness of design (linked to
evidence for effectiveness of cervical cancer screening) in
decreasing order of randomised clinical trial or randomised
population-based trial, cohort studies, case-control studies and
convenience sampling studies.21
Our review was reported according to the Preferred Reporting
Items for Systematic Reviews and Meta-Analyses (PRISMA)22 and
the Meta-analysis of Observational Studies in Epidemiology
(MOOSE) guidelines.23 This review is registered on the PROSPERO
database at the Centre of Reviews and Dissemination, University
of York; registration number CRD42016052119. The full dataset is
available online at (https://doi.org/10.17632/84khm3rf8k.1).
RESULTS
Characteristics of included studies
The review identiﬁed 2502 publications through Medline, Embase
and Cochrane library searches, which reported the association of
the methylation of human genes or of any HPV type with any of
the following outcome groups: CIN2/3, CIN3, CIN2+ and CIN3+
(including ICC) (Fig. 1), of which 877 were duplicates and 1407
were excluded after abstract review, leaving 218 articles for full-
text review. Finally, 43 articles were selected which matched the
inclusion criteria, among which there were at minimum four
reports for any single gene, with the exception of one study
evaluating POU4F3 in a large population-based screening study.24
One study included discrete populations in two countries25 and is
considered as two separate studies. The characteristics of these
studies are summarised in Supplementary Table 2.
Among the 43 included studies and 16,336 women, nine (20.9%)
evaluated DNA methylation as part of population-based screening
among women with screening test abnormality (from here on
referred to as a referral-population-based studies; eight among HR-
HPV-positive women24,26–32 and one among HPV16-positive women
with abnormal cytology33), eight (18.6%) among women enrolled in
cross-sectional or prospective cohort studies,34–41 six (14.0%) using a
case-control design,10,25,42–44 eleven (26%) using convenience
sampling30,45–54 and nine (21%) among women with HPV16
infection (two cohort,55,56 four case-control57–60 and three conve-
nience studies;61–63 Table 1). There was one randomised controlled
non-inferiority trial64 not included in the review, which randomly
allocated women who tested positive for HR-HPV to either triage by
cytology or DNA methylation. As the threshold was pre-deﬁned and
ROC curve was not provided, an earlier study by the same authors
among the same cohort and which provided ROC was included in
the analysis.27
Overall, 20 (47%) studies evaluated DNA methylation
markers among women with a HR-HPV DNA-positive
result,10,24,26–32,35,37,41,42,45,48–52,65 seven (16%) among women
with an abnormal cytology33,39,40,44,46,53,54 and nine (21%)
among women with HPV16 infection55–63 (Table 1). Of the
remaining seven studies, ﬁve evaluated DNA methylation as
primary screening in cohort or case-control studies with high
prevalence of HR-HPV (42%,34 63%,36 76%43 and 80%25) and
one in a convenience study (80% HR-HPV47). One study did not
provide any data on HR-HPV or cytology outcomes.38
The pooled (unadjusted) CIN2+ positivity among 12,552
women in 38 studies was 36.7% and was higher in convenience
studies and in studies involving HPV16-positive women (27.2%,
24.3%, 33.0%, 36.4% and 58.3% in referral-population-based,
cohort, case-control, convenience and HPV16-positive women
studies, respectively; Table 2). The pooled (unadjusted) CIN3+
positivity among 7393 women in 30 studies was 21.5% and was
also higher in convenience and HPV16-positive women studies
(17.4%, 17.7%, 14.8%, 21.5% and 43.1% in referral-population-
based, cohort, case-control, convenience and HPV16-positive
women studies, respectively).
Eleven studies evaluated cell adhesion molecule 1 (CADM1),
myelin and lymphocyte (MAL) and microRNA 124-2 (MIR) in
different combinations26,27,32,34,35,45–50 (Table 1); nine studies
evaluated erythrocyte membrane protein band 4.1 like (EPB41L3)
alone25,28,29,36,51–53,57 and three in combination with DNA
methylation of HPV16 (L1 and L2 regions), HPV18 (L2), HPV31
(L1) and HPV33 (L2), deﬁned as the S5 classiﬁer (a triage classiﬁer
based on DNA methylation of the late regions of HPV16, HPV18,
HPV31 and HPV33 combined with the promoter region of a
human gene EPB41L3);10,33,42 seven for paired box 1 (PAX-1)
alone,38–41,43,44,66 ﬁve for sex-determining region Y, box 1 (SOX-1)
alone29,36,38,41,44 and four for family with sequence similarity
19-member A4 (FAM19A4), one of which was combined with
MIR-124-2.30,31,37,65 There was one large referral-population-based
study evaluating POU Class 4 Homeobox 3 (POU4F3) as a single
human gene DNA methylation for CIN2+ detection.24 Ten studies
reported the association of HPV16 (L1 and/or L2) DNA methylation
with CIN2+/CIN3+.33,55–63 Supplementary Table 3 summarises
the CpG sites targeted for each gene.
The quality of individual studies assessed using QUADAS-2
scores is summarised in Fig. 2, Supplementary Table 1. The
majority of included studies were convenience or case-control
studies, or among women with HPV16 infection only, and many
of these studies had an overrepresentation of women with
CIN2+. In 15 (35%) studies, histological veriﬁcation was available
for all women (i.e. colposcopy-directed biopsies were taken
when indicated and random biopsies taken from women with
normal colposcopy ﬁndings), and the remaining studies had
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histological veriﬁcation only among women for whom biopsy
was indicated following an abnormal colposcopy result (Sup-
plementary Table 2).
Associations of individual DNA methylation markers with grade of
cervical intraepithelial neoplasia grade (Analysis 1)
DNA methylation increased with increasing grades of CIN for all
DNA methylation markers (Supplementary Fig. 1). Compared to
women with ≤CIN1, women with CIN2 had an increased risk of
being methylation positive by any of the seven markers (crude
OR= 2.83, 95% CI: 2.01–4.00, I2= 63%; Supplementary Table 4).
Women with CIN3 and ICC were at higher risk of being
methylation-positive compared to women with ≤CIN1 (CIN3
vs. ≤CIN1: crude OR= 7.92, 95% CI: 6.10–10.29, I2= 43%; ICC vs.
≤CIN1: crude OR= 32.11, 95% CI: 22.51–45.79, I2= 0%).
When restricting the analysis to women with CIN2 and CIN3
only, the risk of methylation positivity was higher among
women with CIN3 compared to women with CIN2 (crude OR=
2.95, 95% CI: 2.03–4.27, I2= 71%). This association was observed
for all genes, with the exception of MAL, MIR-124-2 and POU4F3,
although there was a small number of studies included for
these genes.
Meta-analysis of sensitivity and speciﬁcity of DNA methylation
markers for the detection of CIN2+ and CIN3+ (Analysis 2)
When all gene markers were combined, irrespective of threshold
used to deﬁne methylation positivity, the pooled sensitivity and
speciﬁcity estimates for CIN2+ were 63.2% (95% CI: 56.4–69.5) and
75.9% (95% CI: 71.9–79.5), respectively (Table 2, Supplementary
Fig. 2). The corresponding estimates for CIN3+ were 70.5% (95%
CI: 64.8–75.6) and 74.7% (95% CI: 70.8–78.1; Table 2, Supplemen-
tary Fig. 3). A high degree of heterogeneity was observed among
studies for both outcomes (Table 2).
When restricting to studies allowing standardisation of speci-
ﬁcity at 70%, the pooled sensitivity for CIN2+ and CIN3+ was
68.6% (95% CI: 62.9–73.8) and 71.1% (95% CI: 65.7–76.0),
respectively. At a set speciﬁcity of 50%, the pooled sensitivity
for CIN2+ and CIN3+ was 80.3% (95% CI: 75.6–84.4) and 82.3%
(95% CI: 77.8–86.1), respectively.
When results were stratiﬁed by study design, sensitivity
estimates for CIN2+ were highest for studies focusing on
HPV16-positive women (71.8%, 95% CI: 54.5–84.4) with similar
high speciﬁcity (73.5, 95% CI: 66.6–79.4; Table 2); 8 of these studies
evaluated HPV16/L1 methylation55,56,58–63 and one study evalu-
ated EPB41L3.57 For CIN3+, sensitivity was highest for cohort
studies (Table 2), although these estimates were not adjusted for
gene target, which may have inﬂuenced the ﬁndings. Assessment
of individual gene performance was not possible for each of the
target genes but among those that had sufﬁcient number of
studies, the sensitivity for CIN2+ detection was highest for HPV16
L1/L2 DNA methylation among women positive for HPV16
(sensitivity: 73.5%, 95% CI: 57.3–85.2; speciﬁcity: 72.8%, 95% CI:
65.9–78.7). Among all women, irrespective of HPV16 test positivity,
EPB41L3 and FAM19A4 had the highest sensitivity (60.2% and
60.0%, respectively) with high speciﬁcity (74.6% and 73.0%,
respectively; Supplementary Table 5).
Meta-analysis of positive predictive value of DNA methylation
markers for the detection of CIN2+ and CIN3+ (Analysis 2)
Based on the observed pooled CIN2+ prevalence of 36.7% among
all studies, the pooled PPV for CIN2+ detection was 57.6% (95% CI:
50.3–64.6; Table 3), and this varied according to study design
(43.4%, 45.0%. 51.5%, 59.6% and 79.0% for referral-population-
based, cohort, case-control, convenience and HPV16-positive
women studies, respectively; Model 1; Supplementary Table 6)
reﬂecting the difference in CIN2+ prevalence in these studies.
When a ﬁxed (expected) CIN2+ prevalence of 30% was included
in the model (Model 2), the pooled PPV was 52.9% (95% CI:
48.4–57.4; Table 3). When restricting analysis to studies reporting
threshold to achieve 70% speciﬁcity and 50% speciﬁcity, the
pooled PPV was 38.6% (95% CI: 29.1–48.1), and 40.4% (39.0–41.8),
respectively (Table 3). Based on the observed pooled CIN3+
prevalence of 21.6%, the pooled PPV was 40.8% (95% CI:
33.9–48.0), and similarly varied according to study design
(Supplementary Table 6).
Performance of methylation markers relative to cytology and
HPV16/18 genotyping (Analysis 3)
In 11 studies, which compared the performance of DNA
methylation and cervical cytology among HR-HPV-positive
women, DNA methylation assays were marginally less sensitive
for CIN2+ and CIN3+ detection compared to cytology ASCUS+
(DNA methylation versus ASCUS+: relative sensitivity= 0.81, 95%
CI: 0.63–1.04 [CIN2+]; 0.87, 95% CI: 0.65–1.17 [CIN3+]) but more
speciﬁc (relative speciﬁcity= 1.25, 95% CI: 0.99–1.59 [CIN2+]; 1.37,
95% CI: 1.02–1.85; p= 0.04 [CIN3+]). Similarly, relative sensitivity
of DNA methylation was lower and relative speciﬁcity was higher
for CIN2+/CIN3+ when compared to a cytology cut-off of LSIL+,
although there were fewer studies (Table 4).
In nine studies which directly compared DNA methylation and
HPV16/18 genotyping among HR-HPV-positive women, DNA
methylation assays were signiﬁcantly more sensitive than
HPV16/18 genotyping for CIN2+ (relative sensitivity= 1.22, 95%
CI: 1.05–1.42 p= 0.01) with similar speciﬁcity (relative speciﬁcity=
1.03, 95% CI: 0.94–1.13).
In 10 studies that evaluated DNA methylation assays compared
to HR-HPV DNA cocktail screening tests, methylation assays were
signiﬁcantly less sensitive for CIN2+ (relative sensitivity= 0.58,
95% CI: 0.47–0.72; p < 0.001) but had signiﬁcantly higher
speciﬁcity (relative speciﬁcity= 1.63, 95% CI: 1.30–2.05; p < 0.001).
DISCUSSION
This meta-analysis investigating the performance of DNA methyla-
tion of human genes and HPV virus for the detection of CIN2+
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Fig. 1 Flowchart for study selection. *studies evaluated a combina-
tion of human genes and/or HPV16.
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and CIN3+ indicates that DNA methylation of several human
genes and HPV16 L1/L2 increased with increasing CIN grade, with
signiﬁcantly higher methylation in CIN3 compared to CIN2, and
almost universally high methylation in ICC, conﬁrming the
relevance of these markers as potentially useful in the screening
and triage settings for the most advanced lesions.
At an expected CIN2+ and CIN3+ prevalence of ~30 and 20%,
equivalent for example to a referral-population of women with a
HR-HPV-positive test,27,33 DNA methylation assays had marginally
lower sensitivity for CIN2+ detection and higher speciﬁcity
compared to cytology (ASCUS+ or LSIL+) and higher sensitivity
compared to HPV16/18 genotyping for a similar speciﬁcity.
Although there were too few studies to conduct a discrete
meta-analysis, the S5 classiﬁer had higher sensitivity for CIN2+
detection compared to the human gene EPB41L3 alone without
compromising speciﬁcity,33,42 suggesting the combination of viral
and host cell targets may improve accuracy to detect CIN2+.
Future studies may evaluate methylation of a wider range of HPV
types found to be associated with CIN2+.
An optimal triage test should have high sensitivity to ensure
women with conﬁrmed high-grade lesions receive appropriate
management and high PPV to ensure women who test positive
are accurately targeted for management, avoiding overtreat-
ment, associated costs and patient anxiety. In our review, DNA
methylation assays generated a pooled PPV of 53 and 35% for
CIN2+ and CIN3+, with corresponding sensitivity of 69 and 71%,
respectively. These estimates are similar to that reported for
cytology ASCUS+ among 535 HR-HPV-positive women enrolled
in a population-based screening study in the Netherlands,67 that
reported PPV and sensitivity of 60 and 63%, respectively, for
CIN2+ and 42 and 71%, respectively, for CIN3+. The corre-
sponding estimates for HPV16/18 genotyping were 38 and 59%,
respectively, for CIN2+, and 26 and 65%, respectively, for CIN3+.
Among 614 HR-HPV-positive women participating in the
Canadian Cervical Cancer Screening Trial,68 cytology ASCUS+
had a lower PPV of 30% with a low sensitivity (48%) for CIN2+,
while HPV16/18 genotyping had a PPV and sensitivity of 32 and
64%, respectively. There were too few prospective studies
evaluating DNA methylation markers to conclusively assess their
potential as predictors of future or progressing cervical lesions.
However, three recent studies highlight their potential useful-
ness in that regard. A longitudinal study among 1040 HPV-
positive women enrolled in the POBASCAM screening trial in the
Netherlands reported that, compared to a cytology negative
(<ASCUS) result at enrolment, a negative FAM19A4/MIR124-2
methylation test indicated lower risk of cervical cancer incidence
over a 14-year follow-up period (Risk Ratio= 0.74, 95% CI:
0.16–1.40).69 In a cohort of women living with HIV in South
Africa, participants with persistent CIN3, or CIN2 which
progressed to CIN3, had signiﬁcantly higher baseline EPB41L3
methylation levels compared to women who remained ≤CIN1
over 16 months, and compared to women with spontaneous
regression to ≤CIN1.25 In a study among 149 women with CIN2
that were followed over 2 years in Finland, the S5-classiﬁer had
the highest sensitivity to predict CIN2 lesions that progressed to
CIN3 from those that spontaneously regressed to ≤CIN1
compared to cytology (using various cut points), HPV16/18 or
HPV16/18/31/33 genotyping.70
In comparison to other triage tests such as cytology and
p16INK4A staining, the advantages afforded by DNA methylation
assays are that their molecular basis makes them automatable
and less prone to training and interpretational errors than the
morphological tests. Testing can be performed using the same
clinician-collected or self-collected sample used for HPV screen-
ing,30 thereby simplifying sample collection. Methylation could
therefore become a useful alternative to cytology as a triage test
among HR-HPV-positive women. Moreover, methylation assays
provide an advantage over HPV16/18 genotyping as they are
not restricted to detection of CIN2+ associated with HPV16/18
only, combining a higher sensitivity for CIN2+ with a
similar speciﬁcity. While current methylation technologies may
not yet be suitable for low-resource settings, technological
advances may allow for use in such settings in the not too
distant future.
There were too few studies in our review allowing for an
evaluation of DNA methylation assays as a primary screening test.
However, eleven studies evaluating human genes DNA methyla-
tion assays among populations with high HR-HPV prevalence have
shown that these assays had higher speciﬁcity compared to
primary HPV DNA screening, albeit with lower sensitivity. Assays
combining human genes and HPV viral methylation may therefore
increase sensitivity for CIN2+ detection while retaining high
speciﬁcity, a useful feature in populations with high prevalence of
HR-HPV. Given the potential for self-sampling, this approach may
allow for a one-sample one-visit screening, which would reduce
the loss-to-follow-up of women in many low-resource settings
where HR-HPV prevalence may be high and where access to
screening may be limited, allowing the number of screening visits
in a woman’s lifetime to be reduced. It is important, however, that
any recommendations for inclusion of methylation tests in
screening or triage will have to consider affordability, cost-
effectiveness and ease of management.
There were a number of limitations to our review. Firstly, there
was signiﬁcant heterogeneity in the pooled performance estimates,
Participant selection fully described
Description of women lost-to-follow up
Study population enriched for CIN2+
Study avoided inappropriate exclusions
Methylation assay (index test) well described
Histology endpoint (reference test) well described
QA/QC of histology conducted
Biopsy indication maximises possibility for histological verification
All women had histological endpoint
0%
Yes No Unclear
20% 40% 60% 80% 100%
Fig. 2 Quality assessment of included studies
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which may be explained by any of the following: (1) variability in
study designs; (2) variability in the proportion of CIN2+ cases
included in each study; (3) differences in the target genes and CpG
sites studied and (4) variation in thresholds used to deﬁne
methylation positivity. We sought to limit the effects of these
variations in our analysis. We stratiﬁed performance estimates by
study design to distinguish the performance of DNA methylation in
studies that are in an early discovery phase (i.e. mostly convenience
and case-control studies) from those studies focused on deﬁning the
performance of these markers for screening or triage in referral-
population-based and cohort studies. In order to adjust for
differences in methylation threshold levels, we derived pooled
sensitivity from those studies that allowed us to set speciﬁcity at
70%. Where possible, we obtained pooled sensitivity for individual
target genes that revealed differences in sensitivity, with higher
sensitivity achieved with combination markers compared to
individual genes. Because PPV estimates correlate with prevalence
of disease, we observed heterogeneity in the PPV estimates, largely
due to the variability in the proportion of CIN2 cases included in
each study. We controlled for this variability by generating a pooled
PPV for different ﬁxed levels of CIN2+ and CIN3+. We assumed no
change in performance of DNA methylation assays with increasing
prevalence of CIN2+, although future studies may demonstrate
changes in sensitivity and/or speciﬁcity for CIN2+, depending on
gene target as we currently see for HR-HPV DNA-based tests.
Second, this review may have some selection bias, as we limited
ourselves to include the most widely studied target genes, and a
minimum number of reports for each gene. There was clear
overrepresentation of women enrolled in large studies in the
Netherlands (PROHTECT and POBASCAM) and the UK (PREDICTORS-
1 and -2), as these groups have been most active in this particular
ﬁeld. The associations of individual gene marker methylation with
increasing CIN grades is limited by the low number of studies for
several gene targets included in the analysis, and we were unable to
present adjusted estimates. Finally, not all studies (35% of studies
only) had histological endpoints for all women included in the
analysis, as biopsy indication was often based on colposcopy
ﬁndings, leading to some disease misclassiﬁcation linked to the
variable sensitivity of cytology and colposcopy.71
In conclusion, DNA methylation assays show promise for the
detection of CIN2+ in triage situations, combined with existing
screening tools with high sensitivity but lower speciﬁcity, such as
HPV DNA tests. Methylation could be a useful alternative to cytology
as a triage test among HR-HPV-positive women, given their similar
performance with the added advantages of objectivity, automation
and self-collected sampling. Despite an increasing number of studies
in recent years evaluating different gene targets, the strength of
current evidence remains low, and randomised controlled trials and
further large prospective studies following guidelines on rigorous
biomarker evaluation72 are needed.
AUTHOR CONTRIBUTIONS
H.K., P.M. and A.L. conceptualised the study and developed the research protocol; H.
K. and A.L. identiﬁed articles for full-text review; H.K. and A.L. extracted data from
studies that matched inclusion criteria; H.K. and Y.B.M. did the statistical analyses; All
contributed to the writing of the manuscript.
ADDITIONAL INFORMATION
Supplementary information is available for this paper at https://doi.org/10.1038/
s41416-019-0593-4.
Competing interests: The authors declare no competing interests.
Ethics approval and consent to participate: This systematic review and meta-
analysis used previous published data and did not use any unpublished data. As
such, ethical approval to conduct the analysis was not sought.Ta
bl
e
4.
Po
o
le
d
re
la
ti
ve
se
n
si
ti
vi
ty
an
d
re
la
ti
ve
sp
ec
iﬁ
ci
ty
o
f
D
N
A
m
et
h
yl
at
io
n
as
sa
ys
co
m
p
ar
ed
to
cy
to
lo
g
y
an
d
H
PV
16
/1
8
g
en
o
ty
p
in
g
fo
r
d
et
ec
ti
o
n
o
f
C
IN
2+
an
d
C
IN
3+
fo
llo
w
in
g
a
H
R-
H
PV
-
p
o
si
ti
ve
re
su
lt
,a
n
d
co
m
p
ar
ed
to
H
R
-H
PV
D
N
A
te
st
C
IN
2+
a
C
IN
3+
b
N
st
u
d
ie
s
R
el
at
iv
e
se
n
si
ti
vi
ty
(9
5%
C
I)
p-
va
lu
e
R
el
at
iv
e
sp
ec
iﬁ
ci
ty
(9
5%
C
I)
p-
va
lu
e
N
st
u
d
ie
s
R
el
at
iv
e
se
n
si
ti
vi
ty
(9
5%
C
I)
p-
va
lu
e
R
el
at
iv
e
sp
ec
iﬁ
ci
ty
(9
5%
C
I)
p-
va
lu
e
A
m
on
g
H
R-
H
PV
-p
os
iti
ve
w
om
en
c
C
yt
o
lo
g
y
A
SC
U
S+
1
0
,2
4
–
2
6
,3
1
,3
5
,4
7
,5
1
,5
5
,6
5
11
0.
81
(0
.6
3–
1.
04
)
0.
10
2
1.
25
(0
.9
9–
1.
59
)
0.
11
6
9
0.
87
(0
.6
5–
1.
17
)
0.
35
1
1.
37
(1
.0
2–
1.
85
)
0.
03
7
C
yt
o
lo
g
y
LS
IL
+
2
5
,3
5
,4
4
,4
6
4
0.
65
(0
.4
0–
1.
08
)
0.
09
5
1.
55
(0
.9
2–
2.
61
)
0.
09
6
5
0.
71
(0
.6
1–
0.
82
)
<
0.
00
1
1.
36
(0
.6
9–
2.
68
)
0.
37
1
H
PV
16
/1
8
g
en
o
ty
p
in
g
e
1
0
,2
5
,2
7
,3
0
,3
1
,3
5
,3
6
,4
2
9
1.
22
(1
.0
5–
1.
42
)
0.
01
1.
03
(0
.9
4–
1.
13
)
0.
55
2
8
1.
19
(0
.9
7–
1.
45
)
0.
09
1
1.
04
(0
.9
7–
1.
12
)
0.
23
4
A
m
on
g
al
lw
om
en
irr
es
pe
ct
iv
e
of
H
R-
H
PV
st
at
us
d
H
R
-H
PV
D
N
A
2
5
,3
4
,3
6
,4
0
,4
3
,4
4
,4
6
,4
7
,5
2
,5
4
10
0.
58
(0
.4
7–
0.
72
)
<
0.
00
1
1.
63
(1
.3
0–
2.
05
)
<
0.
00
1
9
0.
71
(0
.6
1–
0.
83
)
<
0.
00
1
1.
66
(1
.2
3–
2.
25
)
0.
00
1
Tw
el
ve
st
u
d
ie
s1
0
,2
4
–
2
6
,3
1
,3
5
,4
4
,4
6
,4
7
,4
9
,5
1
,5
5
,6
5
ev
al
u
at
ed
cy
to
lo
g
y
(a
b
n
o
rm
al
it
ie
s
d
eﬁ
n
ed
as
A
SC
U
S+
in
te
n
st
u
d
ie
s,
LS
IL
+
in
ﬁ
ve
st
u
d
ie
s)
fo
llo
w
in
g
a
H
R
-H
PV
te
st
o
r
am
o
n
g
w
o
m
en
w
it
h
h
ig
h
p
re
va
le
n
ce
o
f
H
R
-H
PV
;
n
in
e1
0
,2
5
,2
7
,3
0
,3
1
,3
5
,3
6
,4
2
ev
al
u
at
ed
H
PV
16
/1
8
g
en
o
ty
p
in
g
fo
llo
w
in
g
a
H
R
-H
PV
-p
o
si
ti
ve
te
st
;t
en
st
u
d
ie
s2
5
,3
4
,3
6
,4
0
,4
3
,4
4
,4
6
,4
7
,5
2
,5
4
ev
al
u
at
ed
p
er
fo
rm
an
ce
o
f
H
R
-H
PV
te
st
in
g
(a
n
y
ty
p
e
p
o
si
ti
ve
u
si
n
g
H
yb
ri
d
C
ap
tu
re
II
o
r
g
en
o
ty
p
in
g
m
et
h
o
d
s)
;
to
en
su
re
st
an
d
ar
d
is
at
io
n
o
f
th
e
ra
w
d
at
a
ac
ro
ss
al
l
o
f
th
e
th
re
e
an
al
ys
es
,w
e
u
se
d
se
n
si
ti
vi
ty
es
ti
m
at
es
b
as
ed
o
n
a
se
t
sp
ec
iﬁ
ci
ty
o
f
70
%
,w
h
er
e
av
ai
la
b
le
a v
s.
≤
C
IN
1
b
vs
.≤
C
IN
2
c T
es
t
ev
al
u
at
ed
am
o
n
g
w
o
m
en
w
it
h
H
R
-H
PV
-p
o
si
ti
ve
te
st
re
su
lt
d
Te
st
ev
al
u
at
ed
am
o
n
g
al
l
w
o
m
en
,i
rr
es
p
ec
ti
ve
o
f
H
R
-H
PV
D
N
A
st
at
u
s
e
In
th
e
an
al
yi
s
co
m
p
ar
in
g
D
N
A
m
et
h
yl
at
io
n
ve
rs
u
s
H
PV
16
/1
8
g
en
o
ty
p
in
g
,t
h
e
co
m
b
in
at
io
n
o
f
D
N
A
m
et
h
yl
at
io
n
as
sa
ys
in
cl
u
d
ed
h
u
m
an
g
en
es
o
n
ly
Performance of DNA methylation assays for detection of high-grade. . .
H Kelly et al.
10
Funding: This work was supported by funding from the European Union
Marie Skłodowska-Curie Actions H2020-MSCA-IF-2017 under grant agreement
796581.
Data availability: Data are available at Mendeley (https://doi.org/10.17632/
84khm3rf8k.1).
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims
in published maps and institutional afﬁliations.
REFERENCES
1. Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., Jemal, A. Global
cancer statistics 2018: GLOBOCAN estimates of incidence and mortality world-
wide for 36 cancers in 185 countries. CA Cancer J. Clin. 68, 394–424 (2018).
https://doi.org/10.3322/caac.21492.
2. WHO. WHO Director-General calls for all countries to take action to help end the
suffering caused by cervical cancer. http://www.who.int/reproductivehealth/call-
to-action-elimination-cervical-cancer/en/. (2018).
3. Sankaranarayanan, R., Nene, B. M., Shastri, S. S., Jayant, K., Muwonge, R., Budukh,
A. M. et al. HPV screening for cervical cancer in rural India. N. Engl. J. Med. 360,
1385–1394 (2009).
4. Giorgi-Rossi, P., Franceschi, S. & Ronco, G. HPV prevalence and accuracy of HPV
testing to detect high-grade cervical intraepithelial neoplasia. Int. J. Cancer 130,
1387–1394 (2012).
5. Waller, J., McCaffery, K., Kitchener, H., Nazroo, J. & Wardle, J. Women’s experiences
of repeated HPV testing in the context of cervical cancer screening: a qualitative
study. Psychooncology 16, 196–204 (2007).
6. Lorincz, A. T. Virtues and weaknesses of DNA methylation as a test for cervical
cancer prevention. Acta Cytol. 60, 501–512 (2016). [Epub 3 Nov 2016].
7. Steenbergen, R. D., Snijders, P. J., Heideman, D. A. & Meijer, C. J. Clinical impli-
cations of (epi)genetic changes in HPV-induced cervical precancerous lesions.
Nat. Rev. Cancer 14, 395–405 (2014).
8. Mirabello, L., Sun, C., Ghosh, A., Rodriguez, A. C., Schiffman, M., Wentzensen, N.
et al. Methylation of human papillomavirus type 16 genome and risk of cervical
precancer in a Costa Rican population. J. Natl Cancer Inst. 104, 556–565 (2012).
9. Wentzensen, N., Sherman, M. E., Schiffman, M. & Wang, S. S. Utility of methylation
markers in cervical cancer early detection: appraisal of the state-of-the-science.
Gynecol. Oncol. 112, 293–299 (2009).
10. Cook, D. A., Krajden, M., Brentnall, A. R., Gondara, L., Chan, T., Law, J. H. et al.
Evaluation of a validated methylation triage signature for human papillomavirus
positive women in the HPV FOCAL cervical cancer screening trial. Int. J. Cancer.
144, 2587–2595 (2018).
11. Clarke, M. A., Wentzensen, N., Mirabello, L., Ghosh, A., Wacholder, S., Harari, A.
et al. Human papillomavirus DNA methylation as a potential biomarker for cer-
vical cancer. Cancer Epidemiol. Biomark. Prev. 21, 2125–2137 (2012).
12. Arbyn, M., Sankaranarayanan, R., Muwonge, R., Keita, N., Dolo, A., Mbalawa, C. G.
et al. Pooled analysis of the accuracy of ﬁve cervical cancer screening tests
assessed in eleven studies in Africa and India. Int. J. Cancer 123, 153–160 (2008).
13. Egger, M., Smith, G. D. & Phillips, A. N. Meta-analysis: principles and procedures.
BMJ 315, 1533–1537 (1997).
14. Reitsma, J. B., Glas, A. S., Rutjes, A. W., Scholten, R. J., Bossuyt, P. M. &
Zwinderman, A. H. Bivariate analysis of sensitivity and speciﬁcity produces
informative summary measures in diagnostic reviews. J. Clin. Epidemiol. 58,
982–990 (2005).
15. Rutter, C. M. & Gatsonis, C. A. A hierarchical regression approach to meta-analysis
of diagnostic test accuracy evaluations. Stat. Med. 20, 2865–2884 (2001).
16. Leeﬂang, M. M., Deeks, J. J., Rutjes, A. W., Reitsma, J. B. & Bossuyt, P. M. Bivariate
meta-analysis of predictive values of diagnostic tests can be an alternative to
bivariate meta-analysis of sensitivity and speciﬁcity. J. Clin. Epidemiol. 65,
1088–1097 (2012).
17. Altman, D. G. & Bland, J. M. Diagnostic tests 2: Predictive values. BMJ 309, 102
(1994).
18. Cheng, H. & Macaluso, M. Comparison of the accuracy of two tests with a
conﬁrmatory procedure limited to positive results. Epidemiology 8, 104–106
(1997).
19. Takwoingi, Y., Deeks, JJ. METADAS:A SAS macro for meta-analysis of diagnostic
accuracy studies. Diagnostic Test Accuracy Working Group. (2010). http://citeseerx.
ist.psu.edu/viewdoc/download?doi=10.1.1.470.1564&rep=rep1&type=pdf.
20. Whiting, P. F., Rutjes, A. W., Westwood, M. E., Mallett, S., Deeks, J. J., Reitsma, J. B.
et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy
studies. Ann. Intern Med. 155, 529–536 (2011).
21. Arbyn, M., Ronco, G., Cuzick, J., Wentzensen, N. & Castle, P. E. How to evaluate
emerging technologies in cervical cancer screening? Int. J. Cancer 125,
2489–2496 (2009).
22. Moher, D., Liberati, A., Tetzlaff, J. & Altman, D. G. Preferred reporting items for
systematic reviews and meta-analyses: the PRISMA statement. BMJ 339, b2535
(2009).
23. Stroup, D. F., Berlin, J. A., Morton, S. C., Olkin, I., Williamson, G. D., Rennie, D. et al.
Meta-analysis of observational studies in epidemiology: a proposal for reporting.
Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA
283, 2008–2012 (2000).
24. Kocsis, A., Takacs, T., Jeney, C., Schaff, Z., Koiss, R., Jaray, B. et al. Performance of a
new HPV and biomarker assay in the management of hrHPV positive women:
subanalysis of the ongoing multicenter TRACE clinical trial (n > 6,000) to evaluate
POU4F3 methylation as a potential biomarker of cervical precancer and cancer.
Int. J. Cancer 140, 1119–1133 (2017).
25. Kelly, H., Chikandiwa, A., Warman, R., Segondy, M., Sawadogo, B., Vasiljevic, N.
et al. Associations of human gene EPB41L3 DNA methylation and cervical
intraepithelial neoplasia in women living with HIV-1 in Africa. AIDS 32, 2227–2236
(2018).
26. Verhoef, V. M., van Kemenade, F. J., Rozendaal, L., Heideman, D. A., Bosgraaf, R. P.,
Hesselink, A. T. et al. Follow-up of high-risk HPV positive women by combined
cytology and bi-marker CADM1/MAL methylation analysis on cervical scrapes.
Gynecol. Oncol. 137, 55–59 (2015).
27. Verhoef, V. M., Heideman, D. A., van Kemenade, F. J., Rozendaal, L., Bosgraaf, R. P.,
Hesselink, A. T. et al. Methylation marker analysis and HPV16/18 genotyping in
high-risk HPV positive self-sampled specimens to identify women with high
grade CIN or cervical cancer. Gynecol. Oncol. 135, 58–63 (2014).
28. Vasiljevic, N., Scibior-Bentkowska, D., Brentnall, A. R., Cuzick, J. & Lorincz, A. T.
Credentialing of DNA methylation assays for human genes as diagnostic bio-
markers of cervical intraepithelial neoplasia in high-risk HPV positive women.
Gynecol. Oncol. 132, 709–714 (2014).
29. van Leeuwen, R. W., Ostrbenk, A., Poljak, M., van der Zee, A. G. J., Schuuring, E.,
Wisman, G. B. A. DNA methylation markers as a triage test for identiﬁcation of
cervical lesions in a high risk human papillomavirus positive screening cohort. Int.
J. Cancer. 144, 746–754 (2018). https://doi.org/10.1002/ijc.31897.
30. De Strooper, L. M., Verhoef, V. M., Berkhof, J., Hesselink, A. T., de Bruin, H. M., van
Kemenade, F. J. et al. Validation of the FAM19A4/mir124-2 DNA methylation test
for both lavage- and brush-based self-samples to detect cervical (pre)cancer in
HPV-positive women. Gynecol. Oncol. 141, 341–347 (2016).
31. Luttmer, R., De Strooper, L. M., Berkhof, J., Snijders, P. J., Dijkstra, M. G., Uijterwaal,
M. H. et al. Comparing the performance of FAM19A4 methylation analysis,
cytology and HPV16/18 genotyping for the detection of cervical (pre)cancer in
high-risk HPV-positive women of a gynecologic outpatient population (COMETH
study). Int. J. Cancer 138, 992–1002 (2016).
32. Hesselink, A. T., Heideman, D. A., Steenbergen, R. D., Gok, M., van Kemenade, F. J.,
Wilting, S. M. et al. Methylation marker analysis of self-sampled cervico-vaginal
lavage specimens to triage high-risk HPV-positive women for colposcopy. Int. J.
Cancer 135, 880–886 (2014).
33. Brentnall, A. R., Vasiljevic, N., Scibior-Bentkowska, D., Cadman, L., Austin, J.,
Szarewski, A. et al. A DNA methylation classiﬁer of cervical precancer based on
human papillomavirus and human genes. Int. J. Cancer 135, 1425–1432 (2014).
34. Van Zummeren, M., Kremer, W. W., Van Aardt, M. C., Breytenbach, E., Richter, K. L.,
Rozendaal, L. et al. Selection of women at risk for cervical cancer in an HIV-
infected South African population. AIDS 31, 1945–1953 (2017).
35. De Vuyst, H., Franceschi, S., Plummer, M., Mugo, N. R., Sakr, S. R., Meijer, C. J., et al.
Methylation levels of CADM1, MAL, and MIR124-2 in cervical scrapes for triage of
HIV-infected, high-risk HPV-positive women in Kenya. J. Acquir Immune Deﬁc.
Syndr. 70, 311–318 (2015).
36. Rogeri, C. D., Silveira, H. C. S., Causin, R. L., Villa, L. L., Stein, M. D., de Carvalho, A. C.
et al. Methylation of the hsa-miR-124, SOX1, TERT, and LMX1A genes as biomarkers
for precursor lesions in cervical cancer. Gynecol. Oncol. 150, 545–551 (2018).
37. Bu, Q., Wang, S., Ma, J., Zhou, X., Hu, G., Deng, H. et al. The clinical signiﬁcance of
FAM19A4 methylation in high-risk HPV-positive cervical samples for the detec-
tion of cervical (pre)cancer in Chinese women. BMC Cancer 18, 1182 (2018).
38. Kan, Y. Y., Liou, Y. L., Wang, H. J., Chen, C. Y., Sung, L. C., Chang, C. F. et al. PAX1
methylation as a potential biomarker for cervical cancer screening. Int. J. Gynecol.
Cancer 24, 928–934 (2014).
39. Li, S. R., Wang, Z. M., Wang, Y. H., Wang, X. B., Zhao, J. Q., Xue, H. B. et al. Value of
PAX1 methylation analysis by MS-HRM in the triage of atypical squamous cells of
undetermined signiﬁcance. Asian Pac. J. Cancer Prev. 16, 5843–5846 (2015).
40. Lin, C. J., Lai, H. C., Wang, K. H., Hsiung, C. A., Liu, H. W., Ding, D. C. et al. Testing for
methylated PCDH10 or WT1 is superior to the HPV test in detecting severe
neoplasms (CIN3 or greater) in the triage of ASC-US smear results. Am. J. Obstet.
Gynecol. 204, 21.e1–7 (2011).
Performance of DNA methylation assays for detection of high-grade. . .
H Kelly et al.
11
41. Tian, Y., Yuan, Wu. N. Y., Liou, Y. L., Yeh, C. T., Cao, L., Kang, Y. N. et al. Utility of
gene methylation analysis, cytological examination, and HPV-16/18 genotyping
in triage of high-risk human papilloma virus-positive women. Oncotarget 8,
62274–62285 (2017).
42. Lorincz, A. T., Brentnall, A. R., Scibior-Bentkowska, D., Reuter, C., Banwait, R.,
Cadman, L. et al. Validation of a DNA methylation HPV triage classiﬁer in a
screening sample. Int. J. Cancer 138, 2745–2751 (2016).
43. Xu, J., Xu, L., Yang, B., Wang, L., Lin, X. & Tu, H. Assessing methylation status of
PAX1 in cervical scrapings, as a novel diagnostic and predictive biomarker, was
closely related to screen cervical cancer. Int. J. Clin. Exp. Pathol. 8, 1674–1681
(2015).
44. Lai, H. C., Ou, Y. C., Chen, T. C., Huang, H. J., Cheng, Y. M., Chen, C. H. et al. PAX1/
SOX1 DNA methylation and cervical neoplasia detection: a Taiwanese Gyneco-
logic Oncology Group (TGOG) study. Cancer Med. 3, 1062–1074 (2014).
45. Kim, M. K., Lee, I. H., Lee, K. H., Lee, Y. K., So, K. A., Hong, S. R. et al. DNA
methylation in human papillomavirus-infected cervical cells is elevated in high-
grade squamous intraepithelial lesions and cancer. J. Gynecol. Oncol. 27, e14
(2016).
46. van Baars, R., van der Marel, J., Snijders, P. J., Rodriquez-Manfredi, A., ter Harmsel,
B., van den Munckhof, H. A. et al. CADM1 and MAL methylation status in cervical
scrapes is representative of the most severe underlying lesion in women with
multiple cervical biopsies. Int. J. Cancer 138, 463–471 (2016).
47. De Strooper, L. M., van Zummeren, M., Steenbergen, R. D., Bleeker, M. C., Hes-
selink, A. T., Wisman, G. B. et al. CADM1, MAL and miR124-2 methylation analysis
in cervical scrapes to detect cervical and endometrial cancer. J. Clin. Pathol. 67,
1067–1071 (2014).
48. De Strooper, L. M., Hesselink, A. T., Berkhof, J., Meijer, C. J., Snijders, P. J., Steen-
bergen, R. D. et al. Combined CADM1/MAL methylation and cytology testing for
colposcopy triage of high-risk HPV-positive women. Cancer Epidemiol. Biomark.
Prev. 23, 1933–1937 (2014).
49. Hesselink, A. T., Heideman, D. A., Steenbergen, R. D., Coupe, V. M., Overmeer,
R. M., Rijkaart, D. et al. Combined promoter methylation analysis of CADM1 and
MAL: an objective triage tool for high-risk human papillomavirus DNA-positive
women. Clin. Cancer Res. 17, 2459–2465 (2011).
50. Overmeer, R. M., Louwers, J. A., Meijer, C. J., van Kemenade, F. J., Hesselink, A. T.,
Daalmeijer, N. F. et al. Combined CADM1 and MAL promoter methylation analysis
to detect (pre-)malignant cervical lesions in high-risk HPV-positive women. Int. J.
Cancer 129, 2218–2225 (2011).
51. Boers, A., Bosgraaf, R. P., van Leeuwen, R. W., Schuuring, E., Heideman, D. A.,
Massuger, L. F. et al. DNA methylation analysis in self-sampled brush material as a
triage test in hrHPV-positive women. Br. J. Cancer 111, 1095–1101 (2014).
52. Eijsink, J. J., Lendvai, A., Deregowski, V., Klip, H. G., Verpooten, G., Dehaspe, L. et al.
A four-gene methylation marker panel as triage test in high-risk human papil-
lomavirus positive patients. Int. J. Cancer 130, 1861–1869 (2012).
53. Boers, A., Wang, R., van Leeuwen, R. W., Klip, H. G., de Bock, G. H., Hollema, H. et al.
Discovery of new methylation markers to improve screening for cervical intrae-
pithelial neoplasia grade 2/3. Clin. Epigenetics. 8, 29 (2016).
54. Huang, T. H., Lai, H. C., Liu, H. W., Lin, C. J., Wang, K. H., Ding, D. C. et al. Quan-
titative analysis of methylation status of the PAX1 gene for detection of cervical
cancer. Int. J. Gynecol. Cancer 20, 513–519 (2010).
55. Lorincz, A. T., Brentnall, A. R., Vasiljevic, N., Scibior-Bentkowska, D., Castanon, A.,
Fiander, A. et al. HPV16 L1 and L2 DNA methylation predicts high-grade cervical
intraepithelial neoplasia in women with mildly abnormal cervical cytology. Int. J.
Cancer 133, 637–644 (2013).
56. Kottaridi, C., Kyrgiou, M., Pouliakis, A., Magkana, M., Aga, E., Spathis, A. et al.
Quantitative measurement of L1 human papillomavirus type 16 methylation for
the prediction of preinvasive and invasive cervical disease. J. Infect. Dis. 215,
764–771 (2017).
57. Louvanto, K., Franco, E. L., Ramanakumar, A. V., Vasiljevic, N., Scibior-Bentkowska,
D., Koushik, A. et al. Methylation of viral and host genes and severity of cervical
lesions associated with human papillomavirus type 16. Int. J. Cancer 136,
E638–E645 (2015).
58. Bryant, D., Hibbitts, S., Almonte, M., Tristram, A., Fiander, A. & Powell, N. Human
papillomavirus type 16 L1/L2 DNA methylation shows weak association with
cervical disease grade in young women. J. Clin. Virol. 66, 66–71 (2015).
59. Mirabello, L., Frimer, M., Harari, A., McAndrew, T., Smith, B., Chen, Z. et al. HPV16
methyl-haplotypes determined by a novel next-generation sequencing method
are associated with cervical precancer. Int. J. Cancer 136, E146–E153 (2015).
60. Mirabello, L., Schiffman, M., Ghosh, A., Rodriguez, A. C., Vasiljevic, N., Wentzensen,
N. et al. Elevated methylation of HPV16 DNA is associated with the development
of high grade cervical intraepithelial neoplasia. Int. J. Cancer 132, 1412–1422
(2013).
61. Qiu, C., Zhi, Y., Shen, Y., Gong, J., Li, Y. & Li, X. High-resolution melting analysis of
HPV-16L1 gene methylation: A promising method for prognosing cervical cancer.
Clin. Biochem. 48, 855–859 (2015).
62. Simanaviciene, V., Popendikyte, V., Gudleviciene, Z. & Zvirbliene, A. Different DNA
methylation pattern of HPV16, HPV18 and HPV51 genomes in asymptomatic HPV
infection as compared to cervical neoplasia. Virology 484, 227–233 (2015).
63. Brandsma, J. L., Harigopal, M., Kiviat, N. B., Sun, Y., Deng, Y., Zelterman, D. et al.
Methylation of twelve CpGs in human papillomavirus type 16 (HPV16) as an
informative biomarker for the triage of women positive for HPV16 infection.
Cancer Prev. Res (Philos.). 7, 526–533 (2014).
64. Verhoef, V. M., Bosgraaf, R. P., van Kemenade, F. J., Rozendaal, L., Heideman, D. A.,
Hesselink, A. T. et al. Triage by methylation-marker testing versus cytology in women
who test HPV-positive on self-collected cervicovaginal specimens (PROHTECT-3): a
randomised controlled non-inferiority trial. Lancet Oncol. 15, 315–322 (2014).
65. De Strooper, L. M., Meijer, C. J., Berkhof, J., Hesselink, A. T., Snijders, P. J., Steen-
bergen, R. D. et al. Methylation analysis of the FAM19A4 gene in cervical scrapes
is highly efﬁcient in detecting cervical carcinomas and advanced CIN2/3 lesions.
Cancer Prev. Res (Philos.). 7, 1251–1257 (2014).
66. Huang, R. L., Chang, C. C., Su, P. H., Chen, Y. C., Liao, Y. P., Wang, H. C. et al.
Methylomic analysis identiﬁes frequent DNA methylation of zinc ﬁnger protein
582 (ZNF582) in cervical neoplasms. PLoS ONE 7, e41060 (2012).
67. Rijkaart, D. C., Berkhof, J., van Kemenade, F. J., Coupe, V. M., Hesselink, A. T.,
Rozendaal, L. et al. Evaluation of 14 triage strategies for HPV DNA-positive women in
population-based cervical screening. Int. J. Cancer 130, 602–610 (2012).
68. Isidean, S. D., Mayrand, M.-H., Ramanakumar, A. V., Rodrigues, I., Ferenczy, A.,
Ratnam, S. et al. Comparison of triage strategies for HPV-positive women:
Canadian cervical cancer screening trial results. Cancer Epidemiol. Biomarkers Prev.
26, 923 (2017)..
69. De Strooper, L. M. A., Berkhof, J., Steenbergen, R. D. M., Lissenberg-Witte, B. I.,
Snijders, P. J. F., Meijer, C. et al. Cervical cancer risk in HPV-positive
women after a negative FAM19A4/mir124-2 methylation test: A post hoc
analysis in the POBASCAM trial with 14 year follow-up. Int J. Cancer 143,
1541–1548 (2018).
70. Louvanto, K., Aro, K., Nedjai, B., Butzow, R., Jakobsson, M., Kalliala, I. et al.
Methylation in predicting progression of untreated high-grade cervical intrae-
pithelial neoplasia. Clin. Infect. Dis. (2019). https://doi.org/10.1093/cid/ciz677.
71. Louwers, J., Zaal, A., Kocken, M., Ter Harmsel, W., Graziosi, G., Spruijt, J. et al.
Dynamic spectral imaging colposcopy: higher sensitivity for detection of pre-
malignant cervical lesions. BJog 118, 309–318 (2011).
72. McShane, L. M., Altman, D. G., Sauerbrei, W., Taube, S. E., Gion, M., Clark, G. M.
et al. Reporting recommendations for tumour MARKer prognostic studies
(REMARK). Br. J. Cancer 93, 387–391 (2005).
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in anymedium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly
from the copyright holder. To view a copy of this license, visit http://creativecommons.
org/licenses/by/4.0/.
© The Author(s) 2019
Performance of DNA methylation assays for detection of high-grade. . .
H Kelly et al.
12
